MedKoo Cat#: 565769 | Name: KAF156

Description:

WARNING: This product is for research use only, not for human or veterinary use.

KAF156 (Ganaplacide) is a drug in development by Novartis for the purpose of treating malaria. It belongs to the class of the imidazolopiperazines. It has shown activity against the Plasmodium falciparum and Plasmodium vivax forms of the malaria parasite. The antimalarial activity of the imidazolopiperazine compound class was initially discovered through a series of sensitive phenotypic antimalarial screens that were developed and run in 2007 and 2008 by a group of biologists working at the Genomics Institute of the Novartis Research Foundation and the Scripps Research Institute.

Chemical Structure

KAF156
KAF156
CAS#1261113-96-5

Theoretical Analysis

MedKoo Cat#: 565769

Name: KAF156

CAS#: 1261113-96-5

Chemical Formula: C22H23F2N5O

Exact Mass: 411.1871

Molecular Weight: 411.46

Elemental Analysis: C, 64.22; H, 5.63; F, 9.23; N, 17.02; O, 3.89

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
KAF156; KAF 156; KAF-156
IUPAC/Chemical Name
2-Amino-1-[3-(4-fluoroanilino)-2-(4-fluorophenyl)-8,8-dimethyl-5,6-dihydroimidazo[1,2-a]pyrazin-7-yl]ethanone
InChi Key
BUPRVECGWBHCQV-UHFFFAOYSA-N
InChi Code
InChI=1S/C22H23F2N5O/c1-22(2)21-27-19(14-3-5-15(23)6-4-14)20(26-17-9-7-16(24)8-10-17)28(21)11-12-29(22)18(30)13-25/h3-10,26H,11-13,25H2,1-2H3
SMILES Code
CC1(C)C2=NC(C3=CC=C(F)C=C3)=C(NC4=CC=C(F)C=C4)N2CCN1C(CN)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 411.46 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: White NJ, Duong TT, Uthaisin C, Nosten F, Phyo AP, Hanboonkunupakarn B, Pukrittayakamee S, Jittamala P, Chuthasmit K, Cheung MS, Feng Y, Li R, Magnusson B, Sultan M, Wieser D, Xun X, Zhao R, Diagana TT, Pertel P, Leong FJ. Antimalarial Activity of KAF156 in Falciparum and Vivax Malaria. N Engl J Med. 2016 Sep 22;375(12):1152-60. doi: 10.1056/NEJMoa1602250. PubMed PMID: 27653565; PubMed Central PMCID: PMC5142602. 2: Huskey SE, Forseth RR, Li H, Jian Z, Catoire A, Zhang J, Ray T, He H, Flarakos J, Mangold JB. Utilization of Stable Isotope Labeling to Facilitate the Identification of Polar Metabolites of KAF156, an Antimalarial Agent. Drug Metab Dispos. 2016 Oct;44(10):1697-708. doi: 10.1124/dmd.116.072108. Epub 2016 Aug 2. PubMed PMID: 27486238. 3: Leong FJ, Jain JP, Feng Y, Goswami B, Stein DS. A phase 1 evaluation of the pharmacokinetic/pharmacodynamic interaction of the anti-malarial agents KAF156 and piperaquine. Malar J. 2018 Jan 5;17(1):7. doi: 10.1186/s12936-017-2162-8. PubMed PMID: 29304859; PubMed Central PMCID: PMC5756412. 4: Kuhen KL, Chatterjee AK, Rottmann M, Gagaring K, Borboa R, Buenviaje J, Chen Z, Francek C, Wu T, Nagle A, Barnes SW, Plouffe D, Lee MC, Fidock DA, Graumans W, van de Vegte-Bolmer M, van Gemert GJ, Wirjanata G, Sebayang B, Marfurt J, Russell B, Suwanarusk R, Price RN, Nosten F, Tungtaeng A, Gettayacamin M, Sattabongkot J, Taylor J, Walker JR, Tully D, Patra KP, Flannery EL, Vinetz JM, Renia L, Sauerwein RW, Winzeler EA, Glynne RJ, Diagana TT. KAF156 is an antimalarial clinical candidate with potential for use in prophylaxis, treatment, and prevention of disease transmission. Antimicrob Agents Chemother. 2014 Sep;58(9):5060-7. doi: 10.1128/AAC.02727-13. Epub 2014 Jun 9. PubMed PMID: 24913172; PubMed Central PMCID: PMC4135840. 5: Koller R, Mombo-Ngoma G, Grobusch MP. The early preclinical and clinical development of ganaplacide (KAF156), a novel antimalarial compound. Expert Opin Investig Drugs. 2018 Oct;27(10):803-810. doi: 10.1080/13543784.2018.1524871. Epub 2018 Sep 25. Review. PubMed PMID: 30223692. 6: Ashley EA, Phyo AP. Drugs in Development for Malaria. Drugs. 2018 Jun;78(9):861-879. doi: 10.1007/s40265-018-0911-9. Review. PubMed PMID: 29802605; PubMed Central PMCID: PMC6013505. 7: Leong FJ, Zhao R, Zeng S, Magnusson B, Diagana TT, Pertel P. A first-in-human randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study of novel Imidazolopiperazine KAF156 to assess its safety, tolerability, and pharmacokinetics in healthy adult volunteers. Antimicrob Agents Chemother. 2014 Nov;58(11):6437-43. doi: 10.1128/AAC.03478-14. Epub 2014 Aug 18. PubMed PMID: 25136017; PubMed Central PMCID: PMC4249437. 8: Lim MY, LaMonte G, Lee MCS, Reimer C, Tan BH, Corey V, Tjahjadi BF, Chua A, Nachon M, Wintjens R, Gedeck P, Malleret B, Renia L, Bonamy GMC, Ho PC, Yeung BKS, Chow ED, Lim L, Fidock DA, Diagana TT, Winzeler EA, Bifani P. UDP-galactose and acetyl-CoA transporters as Plasmodium multidrug resistance genes. Nat Microbiol. 2016 Sep 19;1:16166. doi: 10.1038/nmicrobiol.2016.166. PubMed PMID: 27642791; PubMed Central PMCID: PMC5575994. 9: Held J, Jeyaraj S, Kreidenweiss A. Antimalarial compounds in Phase II clinical development. Expert Opin Investig Drugs. 2015 Mar;24(3):363-82. doi: 10.1517/13543784.2015.1000483. Epub 2015 Jan 7. Review. PubMed PMID: 25563531. 10: Magistrado PA, Corey VC, Lukens AK, LaMonte G, Sasaki E, Meister S, Wree M, Winzeler E, Wirth DF. Plasmodium falciparum Cyclic Amine Resistance Locus (PfCARL), a Resistance Mechanism for Two Distinct Compound Classes. ACS Infect Dis. 2016 Nov 11;2(11):816-826. Epub 2016 Apr 7. PubMed PMID: 27933786; PubMed Central PMCID: PMC5109296. 11: Diagana TT. Supporting malaria elimination with 21st century antimalarial agent drug discovery. Drug Discov Today. 2015 Oct;20(10):1265-70. doi: 10.1016/j.drudis.2015.06.009. Epub 2015 Jun 21. Review. PubMed PMID: 26103616. 12: Mathews ES, Odom John AR. Tackling resistance: emerging antimalarials and new parasite targets in the era of elimination. F1000Res. 2018 Aug 1;7. pii: F1000 Faculty Rev-1170. doi: 10.12688/f1000research.14874.1. eCollection 2018. Review. PubMed PMID: 30135714; PubMed Central PMCID: PMC6073090. 13: Mischlinger J, Agnandji ST, Ramharter M. Single dose treatment of malaria - current status and perspectives. Expert Rev Anti Infect Ther. 2016 Jul;14(7):669-78. doi: 10.1080/14787210.2016.1192462. Epub 2016 Jun 7. Review. PubMed PMID: 27254098. 14: Bhagavathula AS, Elnour AA, Shehab A. Alternatives to currently used antimalarial drugs: in search of a magic bullet. Infect Dis Poverty. 2016 Nov 4;5(1):103. Review. PubMed PMID: 27809883; PubMed Central PMCID: PMC5095999. 15: Rossier J, Nasiri Sovari S, Pavic A, Vojnovic S, Stringer T, Bättig S, Smith GS, Nikodinovic-Runic J, Zobi F. Antiplasmodial Activity and In Vivo Bio-Distribution of Chloroquine Molecules Released with a 4-(4-Ethynylphenyl)-Triazole Moiety from Organometallo-Cobalamins. Molecules. 2019 Jun 21;24(12). pii: E2310. doi: 10.3390/molecules24122310. PubMed PMID: 31234469.